CSL Behring is a global leader in the plasma protein biotherapeutics industry. It specializes in bleeding disorder, fluid replacement, hereditary angioedema, immunoglobulin, pulmonary, and wound healing biotherapies. Its therapies are being used to treat coagulation disorders, primary immune deficiencies, neurological conditions, inherited respiratory diseases and a variety of others. The company was founded in 2000 and is based in King of Prussia, Pennsylvania.